NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

hyperopia, I appreciate your analysis of potential DCVax-L production capacity at Sawston. But, I do have a few questions for you:

Since the Kite facility is producing CAR-T therapies, and the production process for producing autologous dendritic cell therapies is different, would it make more sense to take what NWBio said about the current cold room production capacity, with only about 1/6 of Sawston built-out, is about 400 to 500 patients per year. Then, Flaskworks would increase that production capacity by 10x, up to 4,000 to 5,000 patients per year.

Then, if all of Sawston was built out (6/6 vs only 1/6) and is using Flaskworks, we could scale the production capacity up to 24,000 to 30,000 patients per year.

What do you think?